Prosecution Insights
Last updated: July 17, 2026
Application No. 17/778,935

A METHOD OF FORMING A CONJUGATE OF A SULFONAMIDE AND A POLYPEPTIDE

Non-Final OA §112
Filed
May 23, 2022
Priority
Dec 10, 2019 — EU 19306610.7 +1 more
Examiner
DICKINSON, PAUL W
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sanofi S.A.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
652 granted / 1037 resolved
+2.9% vs TC avg
Moderate +10% lift
Without
With
+9.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
37 currently pending
Career history
1078
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
62.2%
+22.2% vs TC avg
§102
11.6%
-28.4% vs TC avg
§112
6.6%
-33.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1037 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Restriction Requirement Applicant’s election without traverse of Group I in the reply filed on 3/18/2026 is acknowledged. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 5 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. There is no description in the application of what conjugates are obtained by or obtainable from the method of claim 1 so as to describe the genus of conjugates obtained by or obtainable by the method of claim 1. As there is no description of the genus of conjugates obtained by or obtainable by the method of claim 1, the artisan would not accept that applicant had possession of the invention at the time the invention was filed. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, it’s unclear how the appearance of “Ph” within the phenyl ring limits the claim. The artisan would recognize the structure as a phenyl ring, and it’s unclear why the letters “Ph” appear in the formula. It’s therefor unclear if “Ph,” which is not defined by the claim, stands for something else. It is further confusing why the phenyl aromatic ring is labeled and not the neighboring aromatic ring. The examine recommends either removing the “Ph” in the formula or defining the term in the claim. Regarding claim 4, the appearance of “preferably” renders the claim indefinite because it’s unclear if the recitation following the term are positive claim limitations or are merely exemplary. Further regarding claim 4, it’s unclear why “(activated)” is in parentheses and if this is a positive claim limitation or merely exemplary. Further regarding claim 4, the recitation “wherein contacting the aqueous solution… a) is added in solid form to the aqueous solution of b) or at least partially in crystalline form, or at least 90 weight-% in crystallin form.” It’s unclear how one can choose between “ added in solid form” and “or at least partially in crystalline form,” as both of these forms are are solid forms as crystalline materials are solid. It’s further unclear how one can choose between “crystalline form” and “at least 90 weight-% in crystalline form,” as both of these terms are directed to crystalline form. Further regarding claim 4, a broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 4 recites “from 9 to 12” and further recites “from 9.5 to 11.5,” and “from 10 to 11,” which are narrower embodiments of the range/limitation. Further, claim 4 recites “from 9.5 to 11.5,” and also recites “from 10 to 11,” which is a narrower embodiment of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Notes and Comments The closest prior art is Qingqing (Org. Lett. 2019). Although Qingqing teaches a method of functionalization of sulfonamide-containing peptides (pages 5858-5860), it fails to teach or fairly suggest the present method, particularly the structure of Formula (I) required by the present claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL W DICKINSON whose telephone number is (571)270-3499. The examiner can normally be reached on M-F 9 AM to 7:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL W DICKINSON/Primary Examiner, Art Unit 1618 May 30, 2026
Read full office action

Prosecution Timeline

May 23, 2022
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673926
NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING
5y 1m to grant Granted Jul 07, 2026
Patent 12649001
COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES
3y 2m to grant Granted Jun 09, 2026
Patent 12642867
CONJUGATES COMPRISING OCULAR ANGIOGENESIS GROWTH FACTOR APTAMERS AND USES THEREOF IN THE DETECTION AND TREATMENT OF OPHTHALMOLOGICAL ANGIOGENESIS INDICATIONS
6y 9m to grant Granted Jun 02, 2026
Patent 12642875
LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF
5y 10m to grant Granted Jun 02, 2026
Patent 12636384
NANOEMULSION WITH PORPHYRIN SHELL
4y 6m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
73%
With Interview (+9.7%)
3y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1037 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month